Miro clears TGA audit ahead of Crohn’s disease trial

The Sydney Morning Herald - Nov 12, 2026

Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.

Read full article
More News
Business Vantage Views

Business Vantage Views is a dedicated online news network that brings to you the latest state of business and finance so that you can make the best judgment on investment and future planning.